Radiofrequency Neurolysis of the Posterior Nasal Nerve: A Systematic Review and Meta‐Analysis
The Laryngoscope · 2026-12 · 136 (12) · 5199-5210
DOI: 10.1002/lary.70763 ↗Kurz gefasst
Metaanalyse in der Zeitschrift The Laryngoscope, online erschienen am 02.08.2026. Verfasst von Eyad Jamileh und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Queen's University Belfast, Belfast, UK. Hauptthemen laut MEDLINE: Nose, Radiofrequency Ablation, Rhinitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Temperature‐controlled radiofrequency (TCRF) neurolysis of the posterior nasal nerve is a minimally invasive treatment for chronic rhinitis. While early studies show short‐term efficacy, long‐term durability remains unclear. This study evaluated the short‐ and long‐term efficacy and safety of TCRF neurolysis across discrete follow‐up intervals. Data Sources PubMed/MEDLINE, Embase, and the Cochrane Library were searched from inception to March 2026. Review Methods Following PRISMA 2020 guidelines (PROSPERO: CRD420261345320), studies evaluating adults undergoing TCRF neurolysis for chronic rhinitis with quantitative outcomes were included. Random‐effects meta‐analyses pooled outcomes at 3 months, 6 months, 12 months, 2 years, and 3 years.
Results
Twelve studies (924 patients) were included. TCRF neurolysis significantly reduced total nasal symptom scores (rTNSS) across all intervals: 3 months (−3.96, 95% CI −4.26 to −3.67), 6 months (−4.50, 95% CI −4.91 to −4.09), 12 months (−4.70, 95% CI −5.04 to −4.37), 2 years (−5.06, 95% CI −5.67 to −4.44), and 3 years (−4.59, 95% CI −5.00 to −4.19). Symptom responder rates (≥ 30% improvement) rose from 74% at 3 months to 81%–84% during long‐term follow‐up. Mini Rhinoconjunctivitis Quality of Life Questionnaire scores demonstrated sustained improvements up to 3 years. Adverse events were infrequent, minor, and transient.
Conclusion
TCRF neurolysis provides safe, clinically meaningful, and durable improvements in nasal symptoms and quality of life for up to 3 years, offering a robust therapeutic option for medically refractory chronic rhinitis. Level of Evidence 1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Queen's University Belfast, Belfast, UK.
- Royal Blackburn Teaching Hospital; East Lancashire Hospitals Trust, Blackburn, UK.
- School of Medicine, Queen Mary University of London, London, UK.
- Department of Medicine, University of Sheffield, Sheffield, UK.
- Department of Diabetes and Endocrinology, University Hospitals of Leicester NHS Trust, Leicester, UK.
- Department of Medicine, Southend University Hospital, Westcliff-on-Sea, UK.
ORCID-Profile: Eyad Jamileh
Zitieren
APA
Jamileh, E., Muhammad, F., Xamza, M., Ahmed, K., Ahmed, A., & Ahmed, M. (2026). Radiofrequency Neurolysis of the Posterior Nasal Nerve: A Systematic Review and Meta‐Analysis. The Laryngoscope, 136(12), 5199-5210. https://doi.org/10.1002/lary.70763
Vancouver
Jamileh E, Muhammad F, Xamza M, Ahmed K, Ahmed A, Ahmed M. Radiofrequency Neurolysis of the Posterior Nasal Nerve: A Systematic Review and Meta‐Analysis. The Laryngoscope. 2026;136(12):5199-5210. doi:10.1002/lary.70763
BibTeX
@article{Jamileh2026,
author = {Jamileh, Eyad and Muhammad, Fahad and Xamza, Mohamed and Ahmed, Khadijah and Ahmed, Abdullah and Ahmed, Munir},
title = {Radiofrequency Neurolysis of the Posterior Nasal Nerve: A Systematic Review and Meta‐Analysis},
journal = {The Laryngoscope},
year = {2026},
volume = {136},
number = {12},
pages = {5199--5210},
doi = {10.1002/lary.70763}
}
EUVIMED